AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
News Medical on MSN13d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPDA study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...
Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...
Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...
a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...
Free Press Journal on MSN11d
Scientists develop scan that unravels secrets of lung functionOur scans show where there is patchy ventilation in patients with lung disease, and show us which parts of the lung improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback